(TRK-700)-药物靶点：COX-1_在研适应症：疱疹后神经痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TRK700、TRK 700

靶点

COX-1(环氧化酶-1)

作用机制

COX-1抑制剂(环氧化酶-1抑制剂)

治疗领域

神经系统疾病

在研适应症

疱疹后神经痛

非在研适应症-

原研机构

Toray Industries, Inc.

在研机构

Toray Industries, Inc.

非在研机构-

最高研发阶段临床2期

首次获批日期(全球)-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 TRK-700 相关的临床试验

NCT03043248 / Completed临床1期

TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam in Healthy Adults

This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study.
The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a single dose of the P-glycoprotein substrate digoxin (Cohort A) or the CYP3A4 substrate midazolam (Cohort B) during repeated administration of TRK-700 in healthy adult males.

开始日期2017-02-06

申办/合作机构

Toray Industries, Inc.

NCT02701374 / Completed临床2期

TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia -Double Blind Comparison With Placebo-

In Post-Herpetic Neuralgia(PHN) patients:
To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study
To measure the plasma concentration of TRK-700 and its metabolites

开始日期2016-03-01

申办/合作机构

Toray Industries, Inc.

100 项与 TRK-700 相关的临床结果

登录后查看更多信息

100 项与 TRK-700 相关的专利（医药）

登录后查看更多信息

100 项与 TRK-700 相关的药物交易

登录后查看更多信息